Raymond James Reiterates Strong Buy on Liquidia on Supreme Court Case

Raymond James reaffirmed its Strong Buy rating on shares of Liquidia Corporation, the firm announced on June 4, 2026. The analyst action comes days before the United States Supreme Court is scheduled to hear oral arguments in a pivotal patent case between Liquidia and United Therapeutics. The case, which centers on the drug Yutrepia, has significant implications for Liquidia's commercial future and the broader market for pulmonary arterial hypertension treatments. Liquidia's stock closed at $16.45 on June 3, reflecting a year-to-date gain of over 40% as investors anticipate a favorable legal resolution.

Context — why this matters now

The Supreme Court will hear arguments in Liquidia Technologies, Inc. v. United Therapeutics Corporation on June 6, 2026. This is the first time the high court has taken up a patent case directly impacting a pre-commercial pharmaceutical product in over five years, since its 2021 decision in Google LLC v. Oracle America, Inc.. The legal dispute concerns United Therapeutics' method-of-use patents protecting its blockbuster drug, Tyvaso. A decision in Liquidia's favor would remove a final regulatory barrier for its competing product, Yutrepia. The Federal Circuit's previous ruling created the legal ambiguity that prompted the Supreme Court's review, setting the stage for a definitive judgment. The biotech sector is closely watching the case for its potential to clarify patent obviousness standards.

Data — what the numbers show

Liquidia Corporation trades on the NASDAQ under the ticker LTTR. The stock has a market capitalization of approximately $1.2 billion. Shares have surged 42% year-to-date, significantly outperforming the iShares Biotechnology ETF (IBB), which is up 5% over the same period. Raymond James maintains a price target of $22.00 on LTTR, representing a potential 34% upside from the June 3 closing price of $16.45. United Therapeutics, with a market cap exceeding $11 billion, derives a substantial portion of its revenue from Tyvaso, which generated over $1.8 billion in sales in 2025. The following table shows the performance disparity between the two companies in 2026:

Ticker	YTD Performance	Market Cap	Key Product
LTTR	+42%	~$1.2B	Yutrepia (pending)
UTHR	+8%	~$11.5B	Tyvaso

Trading volume for LTTR has averaged 1.5 million shares daily over the past month, 50% above its 90-day average.

Analysis — what it means for markets / sectors / tickers

A Supreme Court ruling for Liquidia would directly benefit the company by enabling the final FDA approval and launch of Yutrepia, creating a new competitor in a multi-billion dollar market. This would pose a significant threat to United Therapeutics' revenue from Tyvaso, potentially pressuring UTHR shares. Generic drugmakers like Teva Pharmaceutical and Mylan could also see positive sentiment, as a ruling narrowing patent scope may simplify pathways for other complex generic and follow-on products. The primary risk to the bullish thesis is an unfavorable ruling that upholds United Therapeutics' patent claims, which would likely delay Yutrepia's launch for years. Institutional positioning data indicates hedge funds have been accumulating LTTR shares in anticipation of a favorable legal outcome, while some long-only funds have reduced exposure to UTHR due to headline risk.

Outlook — what to watch next

The immediate catalyst is the Supreme Court oral argument scheduled for June 6, 2026. While a final decision may not be issued for several months, the tone of the justices' questioning during arguments often signals the eventual outcome. Following the court's decision, the next key date will be the Prescription Drug User Fee Act (PDUFA) action date for Yutrepia, currently set for July 31, 2026. Traders are watching technical support for LTTR at the $15.00 level, which has held twice in the last quarter, with resistance near the 52-week high of $18.50. A break above $18.50 on heavy volume would signal strong conviction in a positive legal resolution.

Frequently Asked Questions

What is the Supreme Court case between Liquidia and United Therapeutics about?

The case challenges the validity of United Therapeutics' patents on Tyvaso. Liquidia argues the patents are an obvious extension of prior art and should not block approval of its similar drug, Yutrepia. The Supreme Court's review focuses on the legal standard for determining when a patent claim is obvious, a decision that could affect pharmaceutical patent strategies industry-wide. The outcome will determine if the FDA can finally approve Yutrepia for commercial sale.

How does a Strong Buy rating from Raymond James affect Liquidia's stock?

A Strong Buy rating from a firm like Raymond James provides institutional validation and can increase visibility among larger investors. It often leads to incremental buying from funds that track analyst recommendations. However, the stock's primary driver remains the Supreme Court case; the rating reflects the analyst's assessment of a favorable risk-reward profile based on that catalyst rather than being a catalyst itself.

What other companies could be affected by the Supreme Court's ruling?

The ruling could impact any company developing follow-on or generic versions of complex drugs, particularly in specialty pharma. Firms like Amphastar Pharmaceuticals and Eagle Pharmaceuticals, which often challenge drug patents, would benefit from a more lenient patent obviousness standard. Conversely, a ruling that strengthens patent holders' rights would be a net positive for innovative biotech firms with strong patent estates, such as Vertex Pharmaceuticals.

Bottom Line

The Supreme Court's impending decision on Liquidia's patent case represents a binary event that will dictate the stock's trajectory for the foreseeable future.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.